Cost-of-illness of patients with systemic sclerosis in a tertiary care centre

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1920-1928

  Minier, Tünde ^a   Péntek, Márta ^b   Brodszky, Valentin ^c   Ecseki, Adrienn ^c   Kárpáti, Krisztián ^c   Polgár, Anna ^d   Czirják, László ^a   Gulácsi, László ^c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Pest Megyei Flor Ferenc Korhaz   (Hungary)

^c Institute of Entrepreneurship and Innovation   (Hungary)

^d NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

Author keywords

Cost drivers; Costs of illness; Disability; Productivity loss; Scleroderma; Systemic sclerosis

Indexed keywords

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC SCLEROSIS; TERTIARY HEALTH CARE;

AGED; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; EFFICIENCY; FEMALE; HEALTH CARE COSTS; HUMANS; HUNGARY; MALE; MIDDLE AGED; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 77956815870     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq165     Document Type: Article

References (25)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Czirjak L, Kumanovics G, Varju C et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
3. Medsger TA Jr. Classification, purpose. In: Clements P, Furst D, eds. Systemic sclerosis. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2004:17-28.
4. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37:223-35.
5. Czirjak L, Kiss CG, Lovei C et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 South-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005;23:801-8.
6. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
7. Nietert PJ, Silverstein MD, Silver RM. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 2001;28: 2031-7.
8. Thombs BD, Bassel M, McGuire L, Smith MT, Hudson M, Haythornthwaite JA. A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. Rheumatology 2008;47:1559-63.
9. Sandqvist G, Scheja A, Eklund M. Working ability in relation to disease severity, everyday occupations and well-being in women with limited systemic sclerosis. Rheumatology 2008;47:1708-11.
10. Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997;27:73-84.
11. Belotti Masserini A, Zeni S, Cossutta R, Soldi A, Fantini F. Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti [Cost-of-illness in systemic sclerosis: a retrospective 40 study of an Italian cohort of 106 patients]. Reumatismo 2003;55:245-55.
12. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8(Suppl. 2): S49-60.
13. Tyndall A, Ladner UM, Matucci-Cerinic M. The EULAR Scleroderma Trials and Research Group (EUSTAR): an international framework for accelerating scleroderma research. Curr Opin Rheumatol 2008;20:703-6.
14. Walker UA, Tyndall A, Czirjak L et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) Group database. Ann Rheum Dis 2009;68: 856-62.
15. Valentini G, Bencivelli W, Bombardieri S et al. European scleroderma study group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
16. Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
17. Nagy Z, Bálint Z, Farkas H et al. A szisztémás sclerosisos betegek számára készült módosított HAQ kérdo00 ív hazai adaptációja és validálása [The adaptation and validation of Scleroderma Health Assessment Questionnaire for Hungarian systemic sclerosis patients]. Magyar Reumatológia 2007;48:208-18.
18. Szende A, Németh R. Health-related quality of life of the Hungarian population. Orv Hetil 2003;144:1667-74.
19. Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 2005;23:449-59.
20. Brodszky V, Balint P, Geher P et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;30: 199-205.
21. Shand L, Lunt M, Nihtyanova S et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56: 2422-31.
22. Bernatsky S, Hudson M, Panopalis P et al. The cost of systemic sclerosis. Arthritis Rheum 2009;61:119-23.
23. Nguyen C, Poiraudeau S, Mestre-Stanislas C et al. Employment status and socio-economic burden in systemic sclerosis: a cross-sectional survey. Rheumatology. Advance Access published February 16, 2010, doi:10.1093/rheumatology/kep400.
24. Sandqvist G, Scheja A, Eklund M. Working ability in relation to disease severity, everyday occupations and well-being in women with limited systemic sclerosis. Rheumatology 2008;47:1708-11.
25. Hudson M, Steele R, Lu Y et al. Work disability in systemic sclerosis. J Rheumatol 2009;36:2481-6.